Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (121-130 of 377) with videos related to

Pageof 38
Sort By:
Breast Care (Basel, Switzerland)|May 8, 2014
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German PerspectiveNadia Harbeck, Norbert Marschner, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
Archives of Gynecology and Obstetrics|October 10, 2022
Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 surveyMaggie Banys-Paluchowski, Michael Untch, Natalia Krawczyk, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Journal of the National Cancer Institute|January 17, 2003
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerGottfried Konecny, Giovanni Pauletti, Mark Pegram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsGottfried E Konecny, Y Gloria Meng, Michael Untch, et al.
BMC Medicine|October 11, 2018
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trialInes Stevic, Volkmar Müller, Karsten Weber, et al.
Breast Care (Basel, Switzerland)|January 30, 2026
ABC8 Consensus: Assessment by a German Group of ExpertsNina Ditsch, Michael Untch, Peter A Fasching, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trialSabine Riethdorf, Volkmar Müller, Liling Zhang, et al.
Breast Care (Basel, Switzerland)|December 14, 2011
Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based TherapyXinrong Guo, Sibylle Loibl, Michael Untch, et al.
Pageof 38

Showing results (121-130 of 377) with videos related to

Sort By:
Pageof 38
Breast Care (Basel, Switzerland)|May 8, 2014
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German PerspectiveNadia Harbeck, Norbert Marschner, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
Archives of Gynecology and Obstetrics|October 10, 2022
Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 surveyMaggie Banys-Paluchowski, Michael Untch, Natalia Krawczyk, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Journal of the National Cancer Institute|January 17, 2003
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerGottfried Konecny, Giovanni Pauletti, Mark Pegram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsGottfried E Konecny, Y Gloria Meng, Michael Untch, et al.
BMC Medicine|October 11, 2018
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trialInes Stevic, Volkmar Müller, Karsten Weber, et al.
Breast Care (Basel, Switzerland)|January 30, 2026
ABC8 Consensus: Assessment by a German Group of ExpertsNina Ditsch, Michael Untch, Peter A Fasching, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trialSabine Riethdorf, Volkmar Müller, Liling Zhang, et al.
Breast Care (Basel, Switzerland)|December 14, 2011
Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based TherapyXinrong Guo, Sibylle Loibl, Michael Untch, et al.
Pageof 38